SEEKYO®’s unique technology comprises a molecular platform enabling the custom design of almost any type of therapeutic vector.

This versatile linker technology offers the possibility to design “on demand” the most appropriate targeting assembly in order to treat a given malignancy, based on its unique tumor-associated specificities.

SEEKYO®’s self-immolative linker can gather in a single molecular entity:

  • an anticancer agent
  • a targeting unit
  • an enzymatic trigger

With SEEKYO®, partners are seeking:

  • Solutions to enhance the selectivity /efficacy of their anticancer drugs
  • Optimization of their existing Antibody Drug Conjugates ADC